These newer therapies, including Semaglutide , belong to a group of drugs called GLP-1 agents. Primarily approved for treating high blood sugar, they operate by encouraging the pancreas to release sufficient the hormone insulin and reducing increased sugar levels. Furthermore , their capacity to